CHARLOTTE, N.C., July 16, 2008 (PRIME NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it has completed nearly 75% of the planned enrollment in its Phase II trial of CH-1504 in rheumatoid arthritis (RA) initiated in January 2008. CH-1504 is the lead drug candidate in Chelsea’s portfolio of orally available, non-metabolized antifolate compounds engineered to provide the same potent efficacy as methotrexate (MTX) without the liver and kidney toxicities or tolerability related side effects associated with chronic therapy.
